Brief: Conmed Q2 Adjusted EPS USD 1.15 Vs. IBES Estimate USD 1.12

Conmed

30/07/2025 21:05

Overview

Conmed Q2 sales rise 3.1% yr/yr, beating analyst expectations, per LSEG data

Adjusted EPS for Q2 beats consensus, driven by supply chain improvements

Company raises full-year revenue and adjusted EPS guidance

Outlook

Based on current forex rates, Conmed expects headwinds to be immaterial vs 50-70 bps of headwind previously

Conmed expects 2025 revenue between $1.356 bln and $1.378 bln

Company projects full-year adjusted EPS of $4.40 to $4.55

Foreign currency headwind estimated at 10 cents on EPS

Tariffs expected to reduce EPS by $0.09 in H2 2025

Result Drivers

SUPPLY CHAIN IMPROVEMENTS - Conmed attributes Q2 performance to strengthening supply chain operations, per CEO Patrick J. Beyer

INTERNATIONAL GROWTH - International sales increased by 3.4% yr/yr, contributing to overall revenue growth

PRODUCT MIX - Single-use products saw a 6.6% increase, partially offsetting a decline in capital products

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$342.34 mln
$338.20 mln (6 Analysts)
Q2 Adjusted EPS
Beat
$1.15
$1.12 (6 Analysts)
Q2 EPS
$0.69
Q2 Net Income
$21.42 mln
Q2 Income from Operations
$38.16 mln
Q2 Pretax Profit
$29.92 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Conmed Corp is $69.00, about 27.1% above its July 29 closing price of $50.29

The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release: ID:nBw5v8WZta

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)